Fig. 4

Serum anti-SPP1 autoantibodies of ESCC patients and normal controls in discovery group and validation group. A, C The distribution of sera anti-SPP1 autoantibodies in ESCC and NC in discovery group (A) and validation group (C). B, D ROC curve analysis of serum anti-SPP1 autoantibodies for distinguishing ESCC from NC in discovery group (B) and validation group (D). ESCC, esophageal squamous cell carcinoma; NC, normal controls; ROC, receiver operating characteristic. ***P < 0.01; ****P < 0.001